Q2 2025 Acarix AB Earnings Call Transcript
Good morning, everybody. Thank you for joining the Acarix Q2 2025 earnings update. Appreciate everybody joining. And as usual, we will give a little bit of an update on who we are and what we do for any new investors that are joining us for the first time.
Acarix has the CADScor technology, which is an early cardiac diagnostic tool that is implemented at point-of-care that can help in really rapid assessment of coronary artery disease. We have an incredible negative predictive value that's proven by clinical trials, and we are the only company in the world in this space that has gone head-to-head with the standard of care, which is CTA in our clinical trials.
In those clinical trials, per FDA approval, we have a 96.2% negative predictive value. And in Europe, with the CE mark, we have a 97.2% predictive value. Well on course, and if not better, then more invasive and longer timeline testing for risk stratification in coronary artery disease.
We've been in business for over 15 years, have R&D going for the entire period. We have
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
